Cargando…

Point-of-care detection of SARS-CoV-2 antigen among symptomatic vs. asymptomatic persons: Testing for COVID-19 vs. infectivity

BACKGROUND: Management of the coronavirus disease 2019 (COVID-19) pandemic caused by a novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requires rapid and simple methods to detect COVID-19 patients and identify potential infectors. This study aimed to evaluate the utility of a poin...

Descripción completa

Detalles Bibliográficos
Autores principales: Neukam, Karin, Lucero, Alicia, Gutiérrez-Valencia, Alicia, Amaya, Lucas, Echegoyen, Natalia, Martelli, Antonella, Videla, Cristina, Di Lello, Federico A., Martínez, Alfredo P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619045/
https://www.ncbi.nlm.nih.gov/pubmed/36324442
http://dx.doi.org/10.3389/fpubh.2022.995249
_version_ 1784821189915443200
author Neukam, Karin
Lucero, Alicia
Gutiérrez-Valencia, Alicia
Amaya, Lucas
Echegoyen, Natalia
Martelli, Antonella
Videla, Cristina
Di Lello, Federico A.
Martínez, Alfredo P.
author_facet Neukam, Karin
Lucero, Alicia
Gutiérrez-Valencia, Alicia
Amaya, Lucas
Echegoyen, Natalia
Martelli, Antonella
Videla, Cristina
Di Lello, Federico A.
Martínez, Alfredo P.
author_sort Neukam, Karin
collection PubMed
description BACKGROUND: Management of the coronavirus disease 2019 (COVID-19) pandemic caused by a novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requires rapid and simple methods to detect COVID-19 patients and identify potential infectors. This study aimed to evaluate the utility of a point-of-care (PoC) rapid antigen diagnostic test (Ag-RDT) in these settings. PATIENTS AND METHODS: Individuals who consecutively presented for SARS-CoV-2 testing at a tertiary care center in Buenos Aires, Argentina, underwent PoC Ag-RDT testing and real-time RT-PCR (qRT-PCR) on the same day during June 2021. RESULTS: Of 584 included subjects, 108 (18.5%) were symptomatic for COVID-19 while the remaining presented for miscellaneous reasons unrelated to possible or confirmed contact with a SARS-CoV-2-infected individual. A positive Ag-RDT result was obtained in 26 (24.1%) symptomatic and 7 (1.5%) asymptomatic persons (p < 0.001), which was concordant with qRT-PCR in 105/108 [97.2%, Cohen's kappa coefficient (κ) = 0.927] symptomatic and 467/476 (98.1% κ = 0.563) asymptomatic participants, with a positive percentage agreement (PPA; 95% confidence interval) of 89.7% (71.5–97.3%) and 42.9% (18.8–70.4%), respectively. None of the 11 false-negative diagnoses showed a C(t)-value ≤20. Considering only failures with a C(t)-value below 31 as hypothetical infectivity threshold of 10(5) SARS-CoV-2 RNA copies/mL, concordance was observed in 98.1% (κ = 0.746) in the asymptomatic population, accounting for a PPA of 66.7% (30.9–91%). CONCLUSIONS: PoC Ag-RDT accurately detected active SARS-CoV-2 infection and showed acceptable diagnostic performance in asymptomatic persons potentially spreading infectious virus. Ag-RDT may therefore be useful to slow down or stop transmission by enabling adequate decisions on isolation at a public health level.
format Online
Article
Text
id pubmed-9619045
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96190452022-11-01 Point-of-care detection of SARS-CoV-2 antigen among symptomatic vs. asymptomatic persons: Testing for COVID-19 vs. infectivity Neukam, Karin Lucero, Alicia Gutiérrez-Valencia, Alicia Amaya, Lucas Echegoyen, Natalia Martelli, Antonella Videla, Cristina Di Lello, Federico A. Martínez, Alfredo P. Front Public Health Public Health BACKGROUND: Management of the coronavirus disease 2019 (COVID-19) pandemic caused by a novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requires rapid and simple methods to detect COVID-19 patients and identify potential infectors. This study aimed to evaluate the utility of a point-of-care (PoC) rapid antigen diagnostic test (Ag-RDT) in these settings. PATIENTS AND METHODS: Individuals who consecutively presented for SARS-CoV-2 testing at a tertiary care center in Buenos Aires, Argentina, underwent PoC Ag-RDT testing and real-time RT-PCR (qRT-PCR) on the same day during June 2021. RESULTS: Of 584 included subjects, 108 (18.5%) were symptomatic for COVID-19 while the remaining presented for miscellaneous reasons unrelated to possible or confirmed contact with a SARS-CoV-2-infected individual. A positive Ag-RDT result was obtained in 26 (24.1%) symptomatic and 7 (1.5%) asymptomatic persons (p < 0.001), which was concordant with qRT-PCR in 105/108 [97.2%, Cohen's kappa coefficient (κ) = 0.927] symptomatic and 467/476 (98.1% κ = 0.563) asymptomatic participants, with a positive percentage agreement (PPA; 95% confidence interval) of 89.7% (71.5–97.3%) and 42.9% (18.8–70.4%), respectively. None of the 11 false-negative diagnoses showed a C(t)-value ≤20. Considering only failures with a C(t)-value below 31 as hypothetical infectivity threshold of 10(5) SARS-CoV-2 RNA copies/mL, concordance was observed in 98.1% (κ = 0.746) in the asymptomatic population, accounting for a PPA of 66.7% (30.9–91%). CONCLUSIONS: PoC Ag-RDT accurately detected active SARS-CoV-2 infection and showed acceptable diagnostic performance in asymptomatic persons potentially spreading infectious virus. Ag-RDT may therefore be useful to slow down or stop transmission by enabling adequate decisions on isolation at a public health level. Frontiers Media S.A. 2022-10-17 /pmc/articles/PMC9619045/ /pubmed/36324442 http://dx.doi.org/10.3389/fpubh.2022.995249 Text en Copyright © 2022 Neukam, Lucero, Gutiérrez-Valencia, Amaya, Echegoyen, Martelli, Videla, Di Lello and Martínez. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Neukam, Karin
Lucero, Alicia
Gutiérrez-Valencia, Alicia
Amaya, Lucas
Echegoyen, Natalia
Martelli, Antonella
Videla, Cristina
Di Lello, Federico A.
Martínez, Alfredo P.
Point-of-care detection of SARS-CoV-2 antigen among symptomatic vs. asymptomatic persons: Testing for COVID-19 vs. infectivity
title Point-of-care detection of SARS-CoV-2 antigen among symptomatic vs. asymptomatic persons: Testing for COVID-19 vs. infectivity
title_full Point-of-care detection of SARS-CoV-2 antigen among symptomatic vs. asymptomatic persons: Testing for COVID-19 vs. infectivity
title_fullStr Point-of-care detection of SARS-CoV-2 antigen among symptomatic vs. asymptomatic persons: Testing for COVID-19 vs. infectivity
title_full_unstemmed Point-of-care detection of SARS-CoV-2 antigen among symptomatic vs. asymptomatic persons: Testing for COVID-19 vs. infectivity
title_short Point-of-care detection of SARS-CoV-2 antigen among symptomatic vs. asymptomatic persons: Testing for COVID-19 vs. infectivity
title_sort point-of-care detection of sars-cov-2 antigen among symptomatic vs. asymptomatic persons: testing for covid-19 vs. infectivity
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619045/
https://www.ncbi.nlm.nih.gov/pubmed/36324442
http://dx.doi.org/10.3389/fpubh.2022.995249
work_keys_str_mv AT neukamkarin pointofcaredetectionofsarscov2antigenamongsymptomaticvsasymptomaticpersonstestingforcovid19vsinfectivity
AT luceroalicia pointofcaredetectionofsarscov2antigenamongsymptomaticvsasymptomaticpersonstestingforcovid19vsinfectivity
AT gutierrezvalenciaalicia pointofcaredetectionofsarscov2antigenamongsymptomaticvsasymptomaticpersonstestingforcovid19vsinfectivity
AT amayalucas pointofcaredetectionofsarscov2antigenamongsymptomaticvsasymptomaticpersonstestingforcovid19vsinfectivity
AT echegoyennatalia pointofcaredetectionofsarscov2antigenamongsymptomaticvsasymptomaticpersonstestingforcovid19vsinfectivity
AT martelliantonella pointofcaredetectionofsarscov2antigenamongsymptomaticvsasymptomaticpersonstestingforcovid19vsinfectivity
AT videlacristina pointofcaredetectionofsarscov2antigenamongsymptomaticvsasymptomaticpersonstestingforcovid19vsinfectivity
AT dilellofedericoa pointofcaredetectionofsarscov2antigenamongsymptomaticvsasymptomaticpersonstestingforcovid19vsinfectivity
AT martinezalfredop pointofcaredetectionofsarscov2antigenamongsymptomaticvsasymptomaticpersonstestingforcovid19vsinfectivity